Naamidine A Is an Antagonist of the Epidermal Growth Factor Receptor and an in Vivo Active Antitumor Agent
✍ Scribed by Copp, Brent R.; Fairchild, Craig R.; Cornell, Laurie; Casazza, Ana Maria; Robinson, Simon; Ireland, Chris M.
- Book ID
- 120170752
- Publisher
- American Chemical Society
- Year
- 1998
- Tongue
- English
- Weight
- 68 KB
- Volume
- 41
- Category
- Article
- ISSN
- 0022-2623
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Selective tyrosine kinase inhibitors are regarded as promising antitumor agents for cancer treatment. Iressa® (ZD1839) is an orally active, selective EGFR‐TKI (epidermal growth factor receptor‐tyrosine kinase inhibitor) that blocks signal transduction pathways implicated in cancer cell
## Abstract Overexpression or expression of activating mutations of the epidermal growth factor receptor (EGFR) is common in cancer and correlates with neoplastic progression. The present study employed Affymetrix® oligonucleotide arrays to profile genes induced by ligand‐activated EGFR with the re
Transforming growth factor-␣ (TGF-␣) and epidermal growth factor (EGF) are members of the EGF family of growth factors. They have a common receptor, the EGF receptor. This belongs to the tyrosine kinase group of receptors called the ErbB receptor family. Other members are ErbB-2, ErbB-3, and ErbB-4.